首页 > 最新文献

Journal of Drugs in Dermatology最新文献

英文 中文
Attitudes on, Practices, and Recommendations for Visible Light Protection Amongst Dermatology Practitioners. 皮肤科医生对可见光防护的态度、做法和建议。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.36849/JDD.8159
Sara Abdel Azim, Cleo Whiting, Adam J Friedman

Background: Iron oxides, antioxidants, and pigmentary titanium dioxide are sunscreen additive ingredients that enhance visible light protection, reduce associated hyperpigmentation, and protect against certain photosensitive dermatoses There are currently no standardized recommendations for visible light protection with these additive ingredients, leading to varied clinical recommendations.

Objectives: This study aimed to evaluate dermatology practitioners' counseling practices for visible light protection.

Methods: An electronic survey was distributed to dermatology practitioners. Survey responses were compiled for analysis, and statistical significance was calculated using a standard 95% confidence interval.

Results: 91.68% of 974 respondents actively counsel patients about visible light protection, primarily emphasizing its role in exacerbating pigmentation in patients with melanin-rich skin (70.92%). Of these, 10.34% recommended sunscreens with visible light protective additive ingredients specifically for patients with melanin-rich skin, and 48.89% recommended them for managing melasma or post-inflammatory hyperpigmentation. Iron oxide additive ingredients were most frequently recommended (90.92%), followed by antioxidants (69.08%) and pigmentary TiO2, (58.85%). 8.32% of respondents reported not counseling patients about visible light protection, with major reasons encompassing the lack of standardized guidelines (50.62%), challenges in recommending suitably tinted sunscreens (27.16%), limited availability of sunscreen options (23.46%), and insufficient supportive data (18.52%).

Conclusion: There is a need for increased education and awareness regarding visible light protection strategies and the identification of patients who may benefit the most from a targeted photoprotective strategy. Establishing standardized guidelines and broadening the availability of sunscreen options conferring visible light protection may help address these gaps. J Drugs Dermatol. 2024;23(11):965-971. doi:10.36849/JDD.8159.

背景:氧化铁、抗氧化剂和色素性二氧化钛是防晒霜的添加剂成分,可增强可见光防护、减少相关色素沉着和防止某些光敏性皮肤病:本研究旨在评估皮肤科医生在可见光防护方面的咨询做法:方法:向皮肤科从业人员发放电子调查问卷。结果:91.68%的 974 位受访者回答了问题:在 974 位受访者中,91.68% 的受访者积极向患者提供有关可见光防护的建议,其中 70.92% 的受访者主要强调了可见光防护在加重黑色素丰富皮肤患者色素沉着方面的作用。其中,10.34%的受访者推荐含有可见光防护添加剂成分的防晒霜,专门用于富含黑色素皮肤的患者,48.89%的受访者推荐用于控制黄褐斑或炎症后色素沉着。最常推荐的添加成分是氧化铁(90.92%),其次是抗氧化剂(69.08%)和色素性二氧化钛(58.85%)。8.32%的受访者表示没有向患者提供可见光防护方面的咨询,主要原因包括缺乏标准化指南(50.62%)、难以推荐合适的有色防晒霜(27.16%)、可供选择的防晒霜有限(23.46%)以及支持性数据不足(18.52%):有必要加强有关可见光防护策略的教育和宣传,并确定哪些患者可从有针对性的光防护策略中获益最多。制定标准化指南和扩大具有可见光防护功能的防晒霜的供应范围可能有助于弥补这些不足。J Drugs Dermatol.2024;23(11):965-971. doi:10.36849/JDD.8159.
{"title":"Attitudes on, Practices, and Recommendations for Visible Light Protection Amongst Dermatology Practitioners.","authors":"Sara Abdel Azim, Cleo Whiting, Adam J Friedman","doi":"10.36849/JDD.8159","DOIUrl":"https://doi.org/10.36849/JDD.8159","url":null,"abstract":"<p><strong>Background: </strong>Iron oxides, antioxidants, and pigmentary titanium dioxide are sunscreen additive ingredients that enhance visible light protection, reduce associated hyperpigmentation, and protect against certain photosensitive dermatoses There are currently no standardized recommendations for visible light protection with these additive ingredients, leading to varied clinical recommendations.</p><p><strong>Objectives: </strong>This study aimed to evaluate dermatology practitioners' counseling practices for visible light protection.</p><p><strong>Methods: </strong>An electronic survey was distributed to dermatology practitioners. Survey responses were compiled for analysis, and statistical significance was calculated using a standard 95% confidence interval.</p><p><strong>Results: </strong>91.68% of 974 respondents actively counsel patients about visible light protection, primarily emphasizing its role in exacerbating pigmentation in patients with melanin-rich skin (70.92%). Of these, 10.34% recommended sunscreens with visible light protective additive ingredients specifically for patients with melanin-rich skin, and 48.89% recommended them for managing melasma or post-inflammatory hyperpigmentation. Iron oxide additive ingredients were most frequently recommended (90.92%), followed by antioxidants (69.08%) and pigmentary TiO2, (58.85%). 8.32% of respondents reported not counseling patients about visible light protection, with major reasons encompassing the lack of standardized guidelines (50.62%), challenges in recommending suitably tinted sunscreens (27.16%), limited availability of sunscreen options (23.46%), and insufficient supportive data (18.52%).</p><p><strong>Conclusion: </strong>There is a need for increased education and awareness regarding visible light protection strategies and the identification of patients who may benefit the most from a targeted photoprotective strategy. Establishing standardized guidelines and broadening the availability of sunscreen options conferring visible light protection may help address these gaps. J Drugs Dermatol. 2024;23(11):965-971. doi:10.36849/JDD.8159.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isobutylamido Thiazolyl Resorcinol (Thiamidol) for Combatting Hyperpigmentation: A Systematic Review of Clinical Studies. 异丁胺基噻唑基间苯二酚(噻咪多)用于对抗色素沉着:临床研究的系统回顾。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.36849/JDD.7985
Paytra A Klein, Colin Kincaid, Arash Babadjouni, Natasha A Mesinkovska

Background: Tyrosinase is the rate-limiting enzyme of melanogenesis and thus an ideal inhibitory target for treating hyperpigmentation. There are many commercially available tyrosinase inhibitors with limited clinical efficacy. A recent screen of 50,000 compounds found isobutylamido thiazolyl resorcinol (ITR) to be the most potent inhibitor of human tyrosinase.

Objective: To summarize the current evidence on the efficacy and adverse effects of ITR in treating hyperpigmentation.

Methods: A literature search was conducted using PubMed and Google Scholar databases in June 2022. Fourteen clinical studies investigating the use of topical ITR in hyperpigmentation treatment or prevention were identified.

Results: Most studies (n=13) investigated topical ITR as a treatment, while only one investigated ITR as a preventative measure against hyperpigmentation. All studies (n=14) found ITR to provide statistically significant improvements to hyperpigmentation conditions, including facial hyperpigmentation (n=3), melasma (n=5), post-inflammatory hyperpigmentation (PIH) (n=3), and UV-induced hyperpigmentation (n=3). Evidence suggests that the effective dosage and duration of topical ITR appears to be 0.1% to 0.2% ITR 2 to 4 times daily for 12 to 24 weeks. Successful prevention of UVB-induced hyperpigmentation has been seen following twice-daily topical ITR application for 3 weeks (P<0.001).

Conclusion: Topical ITR can significantly reduce hyperpigmentation, however, the evidence for its use is limited. Further investigation is warranted to identify the optimal dosage and application schedule of ITR, as well as compare the efficacy of ITR vs hydroquinone to determine if ITR is superior to the current standard of care. J Drugs Dermatol. 2024;23(11):986-991.  doi:10.36849/JDD.7985.

背景:酪氨酸酶是黑色素生成的限速酶,因此是治疗色素沉着的理想抑制靶点。市面上有许多酪氨酸酶抑制剂,但临床疗效有限。最近对 50,000 种化合物进行的筛选发现,异丁氨基噻唑基间苯二酚(ITR)是人类酪氨酸酶最有效的抑制剂:总结有关 ITR 治疗色素沉着的疗效和不良反应的现有证据:2022年6月,我们使用PubMed和谷歌学术数据库进行了文献检索。结果:大多数研究(n=13)调查了外用ITR治疗或预防色素沉着的疗效和不良反应:大多数研究(13 项)将 ITR 作为一种治疗方法进行了调查,只有一项研究将 ITR 作为色素沉着的预防措施进行了调查。所有研究(14 项)都发现 ITR 对色素沉着状况有显著改善,包括面部色素沉着(3 项)、黄褐斑(5 项)、炎症后色素沉着(PIH)(3 项)和紫外线引起的色素沉着(3 项)。有证据表明,外用 ITR 的有效剂量和持续时间似乎为 0.1% 至 0.2% ITR,每天 2 至 4 次,持续 12 至 24 周。每天两次外用 ITR,持续 3 周后,可成功预防紫外线引起的色素沉着(P<0.001):结论:局部使用 ITR 可以明显减少色素沉着,但使用的证据有限。有必要进一步研究 ITR 的最佳剂量和使用时间,并比较 ITR 与氢醌的疗效,以确定 ITR 是否优于目前的标准疗法。J Drugs Dermatol.2024;23(11):986-991.  doi:10.36849/JDD.7985.
{"title":"Isobutylamido Thiazolyl Resorcinol (Thiamidol) for Combatting Hyperpigmentation: A Systematic Review of Clinical Studies.","authors":"Paytra A Klein, Colin Kincaid, Arash Babadjouni, Natasha A Mesinkovska","doi":"10.36849/JDD.7985","DOIUrl":"https://doi.org/10.36849/JDD.7985","url":null,"abstract":"<p><strong>Background: </strong>Tyrosinase is the rate-limiting enzyme of melanogenesis and thus an ideal inhibitory target for treating hyperpigmentation. There are many commercially available tyrosinase inhibitors with limited clinical efficacy. A recent screen of 50,000 compounds found isobutylamido thiazolyl resorcinol (ITR) to be the most potent inhibitor of human tyrosinase.</p><p><strong>Objective: </strong>To summarize the current evidence on the efficacy and adverse effects of ITR in treating hyperpigmentation.</p><p><strong>Methods: </strong>A literature search was conducted using PubMed and Google Scholar databases in June 2022. Fourteen clinical studies investigating the use of topical ITR in hyperpigmentation treatment or prevention were identified.</p><p><strong>Results: </strong>Most studies (n=13) investigated topical ITR as a treatment, while only one investigated ITR as a preventative measure against hyperpigmentation. All studies (n=14) found ITR to provide statistically significant improvements to hyperpigmentation conditions, including facial hyperpigmentation (n=3), melasma (n=5), post-inflammatory hyperpigmentation (PIH) (n=3), and UV-induced hyperpigmentation (n=3). Evidence suggests that the effective dosage and duration of topical ITR appears to be 0.1% to 0.2% ITR 2 to 4 times daily for 12 to 24 weeks. Successful prevention of UVB-induced hyperpigmentation has been seen following twice-daily topical ITR application for 3 weeks (P&lt;0.001).</p><p><strong>Conclusion: </strong>Topical ITR can significantly reduce hyperpigmentation, however, the evidence for its use is limited. Further investigation is warranted to identify the optimal dosage and application schedule of ITR, as well as compare the efficacy of ITR vs hydroquinone to determine if ITR is superior to the current standard of care. J Drugs Dermatol. 2024;23(11):986-991.&nbsp; doi:10.36849/JDD.7985.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physician Opinions on Artificial Intelligence Chatbots In Dermatology: A National Online Cross-Sectional Survey of Dermatologists. 医生对皮肤科人工智能聊天机器人的看法:全国皮肤科医生在线横断面调查。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.36849/JDD.8239
Julian Cortes, Taraneh Paravar, Reid Oldenburg

Background: Artificial intelligence chatbots (AIC) have sharply risen in popularity. Dermatology, heavily involving visual, clinical, and pathological pattern-recognition techniques, will be impacted by AIC. Thus, this study aims to categorize the attitudes and beliefs of American dermatologists towards AIC and their potential uses, benefits, and risks.

Methods: An online cross-sectional survey was distributed to dermatologists across the United States. Questions explored opinions on AIC along with perceived benefits, risks, and important considerations for the incorporation of AIC into the practice of dermatology. Demographic data and self-reported understanding of AIC were also collected.

Results: 192 complete responses were received. 53.6% of respondents were female. 44.3% were between ages 30 to 39. 41.1% had 0 to 10 years of experience as attending physicians. 76.5% of participants believed it is somewhat or very likely that AIC will be formally incorporated into dermatology. Higher self-reported understanding of AIC was associated with an increased perceived likelihood of AIC implementation as well as decreased perceived risk associated with AIC. Notably, 86% of respondents believed AIC would impact "patient education," while concerns regarding "misinformation" and "incorrect diagnoses" were prevalent (89% and 78.5%, respectively). Participants anticipated AIC's role primarily in administrative tasks, with 75.7% citing "reduced work burden on physicians" as a potential benefit.

Conclusion: Dermatologists in the United States foresee the integration of AIC into their practice, emphasizing its potential in administrative roles. Concerns revolve around the complexity of medical understanding and effective patient communication. As AIC continues to evolve, ongoing studies are crucial to evaluate their safety and efficacy in dermatological practice. J Drugs Dermatol. 2024;23(11):972-978. doi:10.36849/JDD.8239.

背景:人工智能聊天机器人(AIC人工智能聊天机器人(AIC)的普及率急剧上升。皮肤科主要涉及视觉、临床和病理模式识别技术,将受到 AIC 的影响。因此,本研究旨在对美国皮肤科医生对 AIC 及其潜在用途、益处和风险的态度和信念进行分类:方法:向全美的皮肤科医生发放了一份在线横断面调查问卷。调查问题包括对 AIC 的看法,以及将 AIC 纳入皮肤科实践中的利益、风险和重要考虑因素。此外,还收集了人口统计学数据和对 AIC 的自述理解:结果:共收到 192 份完整的回复。53.6%的受访者为女性。44.3%的受访者年龄在 30 至 39 岁之间,41.1%的受访者拥有 0 至 10 年的主治医师经验。76.5%的参与者认为 AIC 正式纳入皮肤科的可能性较高或很高。自我报告对 AIC 的了解程度越高,则认为实施 AIC 的可能性越大,同时认为与 AIC 相关的风险越小。值得注意的是,86% 的受访者认为 AIC 将对 "患者教育 "产生影响,而对 "错误信息 "和 "错误诊断 "的担忧则十分普遍(分别为 89% 和 78.5%)。受访者预计 AIC 主要在行政工作中发挥作用,75.7% 的受访者认为 "减轻医生的工作负担 "是其潜在好处:结论:美国的皮肤科医生预计 AIC 将融入他们的临床实践,并强调其在行政管理方面的潜力。人们关注的问题主要是医学理解的复杂性和有效的患者沟通。随着 AIC 的不断发展,持续的研究对于评估其在皮肤科实践中的安全性和有效性至关重要。J Drugs Dermatol.2024;23(11):972-978. doi:10.36849/JDD.8239.
{"title":"Physician Opinions on Artificial Intelligence Chatbots In Dermatology: A National Online Cross-Sectional Survey of Dermatologists.","authors":"Julian Cortes, Taraneh Paravar, Reid Oldenburg","doi":"10.36849/JDD.8239","DOIUrl":"https://doi.org/10.36849/JDD.8239","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence chatbots (AIC) have sharply risen in popularity. Dermatology, heavily involving visual, clinical, and pathological pattern-recognition techniques, will be impacted by AIC. Thus, this study aims to categorize the attitudes and beliefs of American dermatologists towards AIC and their potential uses, benefits, and risks.</p><p><strong>Methods: </strong>An online cross-sectional survey was distributed to dermatologists across the United States. Questions explored opinions on AIC along with perceived benefits, risks, and important considerations for the incorporation of AIC into the practice of dermatology. Demographic data and self-reported understanding of AIC were also collected.</p><p><strong>Results: </strong>192 complete responses were received. 53.6% of respondents were female. 44.3% were between ages 30 to 39. 41.1% had 0 to 10 years of experience as attending physicians. 76.5% of participants believed it is somewhat or very likely that AIC will be formally incorporated into dermatology. Higher self-reported understanding of AIC was associated with an increased perceived likelihood of AIC implementation as well as decreased perceived risk associated with AIC. Notably, 86% of respondents believed AIC would impact \"patient education,\" while concerns regarding \"misinformation\" and \"incorrect diagnoses\" were prevalent (89% and 78.5%, respectively). Participants anticipated AIC's role primarily in administrative tasks, with 75.7% citing \"reduced work burden on physicians\" as a potential benefit.</p><p><strong>Conclusion: </strong>Dermatologists in the United States foresee the integration of AIC into their practice, emphasizing its potential in administrative roles. Concerns revolve around the complexity of medical understanding and effective patient communication. As AIC continues to evolve, ongoing studies are crucial to evaluate their safety and efficacy in dermatological practice. J Drugs Dermatol. 2024;23(11):972-978. doi:10.36849/JDD.8239.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey. 克林霉素磷酸酯 1.2%/阿达帕林 0.15%/过氧化苯甲酰 3.1%凝胶在中重度痤疮患者中的应用:患者之旅。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.36849/JDD.8639
Hilary Baldwin, Julie C Harper, Joshua A Zeichner, Zoe D Draelos, Lawrence F Eichenfield, Michael Gold, Linda Stein Gold, Leon H Kircik

Introduction: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination formulation approved for acne treatment. In 3 clinical studies of participants with moderate-to-severe acne, CAB demonstrated superior efficacy to vehicle and component dyads, with good safety and tolerability. Detailed efficacy/safety data from individual clinical study participants are presented.

Methods: In two phase 3 (NCT04214652, NCT04214639) randomized, double-blind, 12-week studies, participants aged at least 9 years with moderate-to-severe acne were randomized to once-daily CAB or vehicle gel. Descriptive data - including lesion count changes, treatment success (at least 2-grade reduction from baseline in Evaluator's Global Severity Score and clear/almost clear skin), compliance, treatment-emergent adverse events (AEs), and cutaneous safety/tolerance assessments - were summarized from 6 CAB-treated cases.

Results: By week 12, all cases achieved >70% lesion reductions, 4/6 achieved treatment success, and 1/6 achieved a 2-grade reduction in severity. All cases were compliant with CAB treatment. No cases reported serious AEs. Transient increases occurred on cutaneous safety and tolerability assessments, with scores generally decreasing back to/below baseline levels by week 12.

Conclusions: In two phase 3 clinical trials, fixed-dose, triple-combination CAB demonstrated good efficacy/safety. All 6 CAB-treated cases achieved substantial (>70%) lesion reductions, with 5/6 achieving treatment success or 2-grade reduction in severity by week 12. Transient cutaneous safety/tolerability severity increases generally resolved to baseline values by week 12. These clinical study cases reinforce the importance of patient education regarding adherence, expectations, and AEs. J Drugs Dermatol. 2024;23(11):1017-1024. doi:10.36849/JDD.8639.

简介局部使用克林霉素磷酸酯 1.2%/阿达帕林 0.15%/过氧化苯甲酰 3.1%(CAB)凝胶是唯一获准用于痤疮治疗的固定剂量三合一配方。在对中度至重度痤疮患者进行的 3 项临床研究中,CAB 的疗效优于载体和双组分,同时具有良好的安全性和耐受性。本文介绍了个别临床研究参与者的详细疗效/安全性数据:在两项为期12周的3期(NCT04214652、NCT04214639)随机双盲研究中,年龄至少9岁的中度至重度痤疮患者被随机分配使用每日一次的CAB或载体凝胶。研究总结了6例CAB治疗病例的描述性数据,包括皮损数量变化、治疗成功率(评价者总体严重程度评分和透明/几乎透明皮肤比基线至少降低2级)、依从性、治疗突发不良事件(AEs)和皮肤安全性/耐受性评估:结果:截至第 12 周,所有病例的皮损均减少了 70%,4/6 的病例治疗成功,1/6 的病例严重程度降低了 2 个等级。所有病例都坚持接受 CAB 治疗。无严重不良反应报告。在皮肤安全性和耐受性评估中,评分出现短暂上升,到第12周时,评分普遍降至/低于基线水平:在两项 3 期临床试验中,固定剂量、三联 CAB 显示出良好的疗效/安全性。所有 6 例 CAB 治疗病例的皮损均大幅减少(70%),其中 5/6 在第 12 周前达到治疗成功或严重程度降低 2 级。一过性皮肤安全性/耐受性严重程度的增加一般在第 12 周前恢复到基线值。这些临床研究病例强化了对患者进行依从性、期望值和不良反应教育的重要性。J Drugs Dermatol.2024;23(11):1017-1024. doi:10.36849/JDD.8639.
{"title":"Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey.","authors":"Hilary Baldwin, Julie C Harper, Joshua A Zeichner, Zoe D Draelos, Lawrence F Eichenfield, Michael Gold, Linda Stein Gold, Leon H Kircik","doi":"10.36849/JDD.8639","DOIUrl":"10.36849/JDD.8639","url":null,"abstract":"<p><strong>Introduction: </strong>Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination formulation approved for acne treatment. In 3 clinical studies of participants with moderate-to-severe acne, CAB demonstrated superior efficacy to vehicle and component dyads, with good safety and tolerability. Detailed efficacy/safety data from individual clinical study participants are presented.</p><p><strong>Methods: </strong>In two phase 3 (NCT04214652, NCT04214639) randomized, double-blind, 12-week studies, participants aged at least 9 years with moderate-to-severe acne were randomized to once-daily CAB or vehicle gel. Descriptive data - including lesion count changes, treatment success (at least 2-grade reduction from baseline in Evaluator's Global Severity Score and clear/almost clear skin), compliance, treatment-emergent adverse events (AEs), and cutaneous safety/tolerance assessments - were summarized from 6 CAB-treated cases.</p><p><strong>Results: </strong>By week 12, all cases achieved &gt;70% lesion reductions, 4/6 achieved treatment success, and 1/6 achieved a 2-grade reduction in severity. All cases were compliant with CAB treatment. No cases reported serious AEs. Transient increases occurred on cutaneous safety and tolerability assessments, with scores generally decreasing back to/below baseline levels by week 12.</p><p><strong>Conclusions: </strong>In two phase 3 clinical trials, fixed-dose, triple-combination CAB demonstrated good efficacy/safety. All 6 CAB-treated cases achieved substantial (&gt;70%) lesion reductions, with 5/6 achieving treatment success or 2-grade reduction in severity by week 12. Transient cutaneous safety/tolerability severity increases generally resolved to baseline values by week 12. These clinical study cases reinforce the importance of patient education regarding adherence, expectations, and AEs. J Drugs Dermatol. 2024;23(11):1017-1024. doi:10.36849/JDD.8639.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost Analysis of Sunscreens Targeted Towards Skin of Color. 针对有色人种皮肤的防晒霜成本分析。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.36849/JDD.8710
Geetha Godwa, Jacob Beer

Skin cancer most commonly affects fair-skinned individuals1; however, it can appear in individuals of all skin tones. Photoprotective behaviors such as applying sunscreen should be practiced by all individuals regardless of skin tone. Herein, the authors discuss the cost and protection of popular sunscreens targeted towards patients with darker skin or skin of color (SOC), and suggest important considerations providers should take into account when advising about sunscreen recommendations for patients with skin of color. J Drugs Dermatol. 2024;23(11):e181-e182. doi:10.36849/JDD.8710e.

皮肤癌最常见于皮肤白皙的人1 ,但也可能出现在任何肤色的人身上。无论肤色如何,所有人都应采取防晒措施,如涂抹防晒霜。在此,作者讨论了针对深肤色或有色人种(SOC)患者的流行防晒霜的成本和保护作用,并提出了医疗服务提供者在向有色人种患者推荐防晒霜时应考虑的重要因素。J Drugs Dermatol.2024;23(11):e181-e182. doi:10.36849/JDD.8710e.
{"title":"Cost Analysis of Sunscreens Targeted Towards Skin of Color.","authors":"Geetha Godwa, Jacob Beer","doi":"10.36849/JDD.8710","DOIUrl":"10.36849/JDD.8710","url":null,"abstract":"<p><p>Skin cancer most commonly affects fair-skinned individuals1; however, it can appear in individuals of all skin tones. Photoprotective behaviors such as applying sunscreen should be practiced by all individuals regardless of skin tone. Herein, the authors discuss the cost and protection of popular sunscreens targeted towards patients with darker skin or skin of color (SOC), and suggest important considerations providers should take into account when advising about sunscreen recommendations for patients with skin of color. J Drugs Dermatol. 2024;23(11):e181-e182. doi:10.36849/JDD.8710e.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
INDIVIDUAL ARTICLE: All for One and One for All: The Three Musketeers of Topical Acne Treatment and the Current Landscape. 个人文章:人人为我,我为人人:痤疮局部治疗三剑客与当前形势。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-11-01
Naiem T Issa, Ali Shahbaz, Leon Kircik

What is the ideal topical acne therapeutic? Topical therapeutics for acne vulgaris have advanced considerably over the last decade. Novel vehicular technologies have increased transdermal penetration of active molecules, enhanced their distribution across the skin surface, improved tolerability, and allowed for the incorporation of previously incompatible active compounds. Thus, fixed-combination topical therapeutics were successfully developed and are able to target multiple aspects of acne pathogenesis leading to synergism and increased efficacy. These advancements have paved the way to optimizing acne treatment while incorporating antibiotic stewardship which has become an urgent necessity. J Drugs Dermatol. 2024;23:11(Suppl 1):s4-10.

什么是理想的痤疮外用疗法?在过去十年中,治疗寻常痤疮的外用疗法取得了长足的进步。新的载体技术提高了活性分子的透皮穿透性,增强了活性分子在皮肤表面的分布,改善了耐受性,并允许加入以前不兼容的活性化合物。因此,固定组合外用疗法得以成功开发,并能针对痤疮发病机制的多个方面发挥协同作用,提高疗效。这些进步为优化痤疮治疗铺平了道路,同时也将抗生素管理纳入其中,这已成为当务之急。J Drugs Dermatol.2024;23:11(Suppl 1):s4-10.
{"title":"INDIVIDUAL ARTICLE: All for One and One for All: The Three Musketeers of Topical Acne Treatment and the Current Landscape.","authors":"Naiem T Issa, Ali Shahbaz, Leon Kircik","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>What is the ideal topical acne therapeutic? Topical therapeutics for acne vulgaris have advanced considerably over the last decade. Novel vehicular technologies have increased transdermal penetration of active molecules, enhanced their distribution across the skin surface, improved tolerability, and allowed for the incorporation of previously incompatible active compounds. Thus, fixed-combination topical therapeutics were successfully developed and are able to target multiple aspects of acne pathogenesis leading to synergism and increased efficacy. These advancements have paved the way to optimizing acne treatment while incorporating antibiotic stewardship which has become an urgent necessity. J Drugs Dermatol. 2024;23:11(Suppl 1):s4-10.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Critical Insights on Preparation of Platelet-Rich Plasma in Tubes With a Thixotropic Gel Separator. 关于在带有触变凝胶分离器的试管中制备富血小板血浆的重要见解。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.36849/JDD.7983
Nicholas J Sadgrove, Jaya Krishna Batra, Sanjay Batra

Thixotropic gels are the preferred choice in the collection of platelet-rich plasma as an easy solution to operator variability. One often unnoticed shortcoming is the entrapment of platelets in the gel layer's uppermost surface. We provide instructions to optimize platelet yield, ie, agitation to re-suspend platelets, setting the optimal G-force and time of centrifugation, and the essential use of a horizontal swing bucket centrifuge. We conclude that this technique represents a new clinical and research direction, particularly to optimize platelet counts. We therefore encourage others to utilize this technique in future endeavors. J Drugs Dermatol. 2024;23(11):979-985. doi:10.36849/JDD.7983.

触变凝胶是收集富血小板血浆的首选,因为它能轻松解决操作者的多变性。一个经常被忽视的缺点是凝胶层最上层表面会夹带血小板。我们提供了优化血小板产量的说明,即搅拌以重新悬浮血小板、设置最佳离心力和时间,以及水平摆桶离心机的基本使用方法。我们的结论是,这项技术代表了一个新的临床和研究方向,尤其是在优化血小板计数方面。因此,我们鼓励其他人在未来的工作中利用这一技术。J Drugs Dermatol.2024;23(11):979-985. doi:10.36849/JDD.7983.
{"title":"Critical Insights on Preparation of Platelet-Rich Plasma in Tubes With a Thixotropic Gel Separator.","authors":"Nicholas J Sadgrove, Jaya Krishna Batra, Sanjay Batra","doi":"10.36849/JDD.7983","DOIUrl":"https://doi.org/10.36849/JDD.7983","url":null,"abstract":"<p><p>Thixotropic gels are the preferred choice in the collection of platelet-rich plasma as an easy solution to operator variability. One often unnoticed shortcoming is the entrapment of platelets in the gel layer's uppermost surface. We provide instructions to optimize platelet yield, ie, agitation to re-suspend platelets, setting the optimal G-force and time of centrifugation, and the essential use of a horizontal swing bucket centrifuge. We conclude that this technique represents a new clinical and research direction, particularly to optimize platelet counts. We therefore encourage others to utilize this technique in future endeavors. J Drugs Dermatol. 2024;23(11):979-985. doi:10.36849/JDD.7983.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Clinical Efficacy and Tolerability of a Novel Retinaldehyde Serum with Firming Peptides to Improve Skin Texture and Signs of Photoaging. 一种含有紧致肽的新型视黄醛精华液在改善皮肤质地和光老化迹象方面的临床疗效和耐受性。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.36849/JDD.8058
Hailey Konisky, Whitney P Bowe, Pada Yang, Kseniya Kobets

Retinoids are derivatives of vitamin A prominently used in cosmeceuticals to reverse signs of photoaging. Retinaldehyde (retinal) is 10x more bioavailable than retinol and is gaining traction in the skincare industry for being the strongest over-the-counter retinoid. This study evaluated the efficacy and tolerability of a novel retinal formulation including peptides, ceramides, and lipids, designed to sustain the potency of the retinal and enhance delivery to reverse clinical signs of photoaging. This study was a trial of the test product (Retinal Night Advanced 0.1% Retinal Firming Treatment, Dr. Whitney Bowe Beauty, Greenwich, CT) in which 32 female subjects were enrolled. 47% of subjects had skin of color (Fitzpatrick Skin Type III-VI) and 57% had sensitive skin. Subjects applied the test product 3 nights weekly to the face, neck, and chest for 8 weeks. Fine lines of the face had 12% visible change by week 8 (P<0.0001). Fine lines on the chest showed progressive visible improvement of 11% at week 2 (P=0.0005) and 19% at week 8 (P<0.0001). There was a 19% improvement in visible hyperpigmentation of the face by the 8-week mark (P<0.0001). Visible texture of the face improved by 5% (P=0.0078) and pores improved by 20% at week 8 (P<0.0001). Patch testing revealed no signs of sensitization or irritation. This clinical study demonstrates that this retinal formulation is safe, well-tolerated, and effective in improving the appearance of fine lines, hyperpigmentation, texture, and pores. J Drugs Dermatol. 2024;23(11):992-997. doi:10.36849/JDD.8058R1 .

视黄醇是维生素 A 的衍生物,在药妆产品中被广泛用于逆转光老化迹象。视黄醛(视黄醛)的生物利用率是视黄醇的 10 倍,是最强的非处方类视黄醛,因此在护肤品行业受到越来越多的关注。这项研究评估了一种新型视黄醛配方的功效和耐受性,该配方包括肽、神经酰胺和脂质,旨在维持视黄醛的功效,并加强输送,以逆转光老化的临床症状。这项研究是对测试产品(Retinal Night Advanced 0.1% Retinal Firming Treatment,Dr. Whitney Bowe Beauty,Greenwich, CT)的试验,共有 32 名女性受试者参加。47%的受试者为有色皮肤(菲茨帕特里克皮肤类型 III-VI),57%的受试者为敏感性皮肤。受试者每周 3 晚在面部、颈部和胸部涂抹测试产品,持续 8 周。到第 8 周时,面部细纹有 12% 的明显变化(P<0.0001)。胸部细纹在第 2 周和第 8 周分别有 11% 和 19% 的明显改善(P<0.0001)。到第 8 周时,面部可见的色素沉着改善了 19%(P<0.0001)。第 8 周时,脸部可见纹理改善了 5%(P=0.0078),毛孔改善了 20%(P<0.0001)。贴片测试未发现过敏或刺激迹象。这项临床研究表明,这种视网膜配方安全、耐受性好,能有效改善细纹、色素沉着、肤质和毛孔。J Drugs Dermatol.2024;23(11):992-997. doi:10.36849/JDD.8058R1 .
{"title":"The Clinical Efficacy and Tolerability of a Novel Retinaldehyde Serum with Firming Peptides to Improve Skin Texture and Signs of Photoaging.","authors":"Hailey Konisky, Whitney P Bowe, Pada Yang, Kseniya Kobets","doi":"10.36849/JDD.8058","DOIUrl":"10.36849/JDD.8058","url":null,"abstract":"<p><p>Retinoids are derivatives of vitamin A prominently used in cosmeceuticals to reverse signs of photoaging. Retinaldehyde (retinal) is 10x more bioavailable than retinol and is gaining traction in the skincare industry for being the strongest over-the-counter retinoid. This study evaluated the efficacy and tolerability of a novel retinal formulation including peptides, ceramides, and lipids, designed to sustain the potency of the retinal and enhance delivery to reverse clinical signs of photoaging. This study was a trial of the test product (Retinal Night Advanced 0.1% Retinal Firming Treatment, Dr. Whitney Bowe Beauty, Greenwich, CT) in which 32 female subjects were enrolled. 47% of subjects had skin of color (Fitzpatrick Skin Type III-VI) and 57% had sensitive skin. Subjects applied the test product 3 nights weekly to the face, neck, and chest for 8 weeks. Fine lines of the face had 12% visible change by week 8 (P&lt;0.0001). Fine lines on the chest showed progressive visible improvement of 11% at week 2 (P=0.0005) and 19% at week 8 (P&lt;0.0001). There was a 19% improvement in visible hyperpigmentation of the face by the 8-week mark (P&lt;0.0001). Visible texture of the face improved by 5% (P=0.0078) and pores improved by 20% at week 8 (P&lt;0.0001). Patch testing revealed no signs of sensitization or irritation. This clinical study demonstrates that this retinal formulation is safe, well-tolerated, and effective in improving the appearance of fine lines, hyperpigmentation, texture, and pores. J Drugs Dermatol. 2024;23(11):992-997. doi:10.36849/JDD.8058R1&nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and Effectiveness of Synchronized Monopolar Radiofrequency and HIFES in Patients Injected With Botulinum Toxin. 注射肉毒杆菌毒素患者使用同步单极射频和 HIFES 的安全性和有效性。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.36849/JDD.7938
Suneel Chilukuri

Background: Botulinum toxin (BT) has become one of the most frequently sought aesthetic procedures for wrinkle reduction.

Objective: This study investigated the effectiveness and safety of a novel device using radiofrequency (RF) and high-intensity facial muscle stimulation (HIFES) in patients injected with BT.

Methods: Twelve patients were divided into an Active (N=10) and a Control group (N=2), where the Active received four treatments and the Control none. The facial expressions documented by digital photographs (neutral) and videos (frown, smile, surprise expressions) were taken at all visits (baseline, after last Tx, 1 and 3-month follow-ups) and were evaluated using the Global Aesthetic Improvement Scale (GAIS) and 3D automated analysis. The subject's therapy comfort and satisfaction were assessed.

Results: The Active group reported high satisfaction with treatment comfort (6.3±0.2 points on the 7-point Likert scale). 3D analysis showed reduced wrinkle severity (37.4%) and volume increase (+1.5 mL) on the cheeks at 3 months. GAIS evaluation demonstrated the most prominent improvement in smiling facial expression by 2.2±0.1 points. No adverse events were observed.

Conclusion: The study results suggest that the combination of HIFES and synchronized RF is a safe and effective treatment for improving facial appearance and muscle tone in patients injected with BT. J Drugs Dermatol. 2024;23(11):937-942.  doi:10.36849/JDD.7938.

背景:肉毒杆菌毒素(BT肉毒杆菌毒素(BT)已成为最常见的除皱美容方法之一:本研究调查了一种使用射频(RF)和高强度面部肌肉刺激(HIFES)的新型设备对注射肉毒杆菌毒素患者的有效性和安全性:将 12 名患者分为主动组(10 人)和对照组(2 人),主动组接受四次治疗,对照组不接受治疗。在所有就诊时间(基线、最后一次治疗后、1 个月和 3 个月的随访)拍摄数码照片(中性)和视频(皱眉、微笑、惊讶表情)记录面部表情,并使用全球美学改善量表(GAIS)和三维自动分析进行评估。此外,还对受试者的治疗舒适度和满意度进行了评估:结果:积极组对治疗舒适度的满意度很高(在 7 点李克特量表上得 6.3±0.2分)。三维分析显示,3 个月后,脸颊的皱纹严重程度降低了 37.4%,容积增加了 +1.5 mL。GAIS评估显示,微笑面部表情的改善最为显著,提高了2.2±0.1分。研究未发现任何不良反应:研究结果表明,联合使用 HIFES 和同步射频是一种安全有效的治疗方法,可改善注射 BT 患者的面部外观和肌肉张力。J Drugs Dermatol.2024;23(11):937-942.  doi:10.36849/JDD.7938.
{"title":"Safety and Effectiveness of Synchronized Monopolar Radiofrequency and HIFES in Patients Injected With Botulinum Toxin.","authors":"Suneel Chilukuri","doi":"10.36849/JDD.7938","DOIUrl":"https://doi.org/10.36849/JDD.7938","url":null,"abstract":"<p><strong>Background: </strong>Botulinum toxin (BT) has become one of the most frequently sought aesthetic procedures for wrinkle reduction.</p><p><strong>Objective: </strong>This study investigated the effectiveness and safety of a novel device using radiofrequency (RF) and high-intensity facial muscle stimulation (HIFES) in patients injected with BT.</p><p><strong>Methods: </strong>Twelve patients were divided into an Active (N=10) and a Control group (N=2), where the Active received four treatments and the Control none. The facial expressions documented by digital photographs (neutral) and videos (frown, smile, surprise expressions) were taken at all visits (baseline, after last Tx, 1 and 3-month follow-ups) and were evaluated using the Global Aesthetic Improvement Scale (GAIS) and 3D automated analysis. The subject's therapy comfort and satisfaction were assessed.</p><p><strong>Results: </strong>The Active group reported high satisfaction with treatment comfort (6.3&plusmn;0.2 points on the 7-point Likert scale). 3D analysis showed reduced wrinkle severity (37.4%) and volume increase (+1.5 mL) on the cheeks at 3 months. GAIS evaluation demonstrated the most prominent improvement in smiling facial expression by 2.2&plusmn;0.1 points. No adverse events were observed.</p><p><strong>Conclusion: </strong>The study results suggest that the combination of HIFES and synchronized RF is a safe and effective treatment for improving facial appearance and muscle tone in patients injected with BT. J Drugs Dermatol. 2024;23(11):937-942.&nbsp; doi:10.36849/JDD.7938.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLP-1 Receptor Agonists for the Dermatologist: Uses and Considerations. 皮肤科医生的 GLP-1 受体激动剂:用途和注意事项。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-11-01
Savanna I Vidal, Nikita Menta, Dillon Nussbaum, Adam Friedman
{"title":"GLP-1 Receptor Agonists for the Dermatologist: Uses and Considerations.","authors":"Savanna I Vidal, Nikita Menta, Dillon Nussbaum, Adam Friedman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Drugs in Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1